Research on new drugs to block endothelin has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. Whether the new drugs can treat ...

The potent vasoconstrictor peptide endothelin-1 (ET-1) was first isolated from the culture media of porcine endothelial cells in 1988 (Yanagisawa et al, 1988). It is one of a family of multifunctional ...

Endothelin-1 (ET-1) is a 21-amino acid polypeptide produced primarily by vascular endothelial cells. First discovered in 1988 as a potent vasoconstrictor, it has subsequently been appreciated to ...

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

LONG BEACH, Calif. -- Two different ocular implants eluting an endothelin antagonist showed early promise for slowing diabetic eye disease, according to two small studies reported here. In a ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well ...

According to the FDA, the labeling alone should be adequate to communicate the risk of embryofetal toxicity. The Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation ...

Please provide your email address to receive an email when new articles are posted on . PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with ...

Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors PATIENTS AND METHODS: Patients who were 18 years or older and ...